“Amlitelimab Reduces Th2-, Th1-, and Th17 22-Related Cytokines and Chemokines in Adults With Moderate-to-Severe Atopic Dermatitis: Results From an Exploratory Analysis of the Phase 2b STREAM-AD Study”. SKIN The Journal of Cutaneous Medicine, vol. 9, no. 6, Nov. 2025, p. s603, https://doi.org/10.25251/x2k3y515.